A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Psoriasis Clinical Trial

Official title:

A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of ABY-035/AFO2 Given as Multiple Doses in Sequential Escalating Dose Cohorts in Psoriasis Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03580278
• Other study ID #: ABY-035-101
• Status: Completed
• Phase: Phase 1
• Start date: November 13, 2019
• Est. completion date: September 22, 2020

Study information

• Verified date: November 2020
• Source: Affibody
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: September 22, 2020
• Est. primary completion date: September 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosed with plaque psoriasis at least 6 months prior to Screening, if suitable for systemic treatment or phototherapy, and if have a stable active plaque-type psoriasis (stable is defined as without clinically significant flares during the 12 weeks before the first dose). Subjects with psoriatic arthritis may be included if they have not received systemic treatment within the last 12 months and their disease is stable
• Subjects must use adequate contraceptive measures from the Screening Visit until 4 weeks after final administration of the investigational product
• Subject that has a maximum body weight of 243 pounds (110 kg)

Exclusion Criteria:

• Subjects with psoriatic arthritis that have received systemic treatment within the last 12 months.
• Subjects will not be eligible if they have current forms of psoriasis other than chronic plaque-type (e.g. erythrodermic, guttate, or pustular)
• Subject that has a current drug-induced psoriasis form (e.g. a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• Subject that has a history of recurrent or medically important infections, a clinically significant candida infection or clinically significant skin infection with Staphylococcus aureus requiring systemic treatment in the last 12 months prior to the first administration of study drug
• Subject that smokes more than 15 cigarettes, or equivalent in tobacco, per day Subject with a history of suicide attempt or suicidal behavior
• Any live vaccination within 3 months prior to Screening
• Subject that is pregnant, intends to become pregnant during the course of the study, or is lactating

Related Conditions & MeSH terms

• Psoriasis

Intervention

Biological:
• ABY-035/AFO2
Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis

Locations

Country	Name	City	State
United States	Raoof, Joseph	Encino	California

Sponsors (1)

Lead Sponsor	Collaborator
Affibody

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with treatment-related Adverse Events as assessed by the principles of Common Terminology Criteria for Adverse Events (CTCAE)	5 male and female psoriasis subjects will be enrolled to obtain who complete treatment or drop out due to adverse events for Cohorts 1 and 2	28 Days
Primary	Number of subjects with treatment-related Adverse Events as assessed by the principles of Common Terminology Criteria for Adverse Events (CTCAE)	20 male and female psoriasis subjects will be enrolled to obtain who complete treatment or drop out due to adverse events for Cohort 3	42 Days
Secondary	Subjects´ level of anti-drug antibodies (ADAs) in the blood	To assess the immunogenicity of ABY-035 after multiple doses of ABY 035/AFO2 in psoriasis subjects	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts
Secondary	If subjects have assessable pharmacokinetics (PK) of ABY-035	To investigate the peak plasma concentration (Cmax ) of ABY-035 after multiple doses of ABY-035/AFO2 in psoriasis subjects	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts
Secondary	If subjects have assessable pharmacokinetics (PK) of ABY-035	To investigate the Area under the curve (AUC) versus time curve of ABY-035/AFO2 in psoriasis subjects	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts
Secondary	Efficacy assessment: The change of the subjects´ scaling of a selected target plaque from baseline to the last visit	The results will be summarized as number and percent by visit. Tables from baseline will be prepared for all timepoints	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts
Secondary	Efficacy assessment: The change of the subjects´erythema of a selected target plaque from baseline to the last visit	The results will be summarized as number and percent by visit. Tables from baseline will be prepared for all timepoints	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts
Secondary	Efficacy assessment: The change of the subjects´ thickness of a selected target plaque from baseline to the last visit	The results will be summarized as number and percent by visit. Tables from baseline will be prepared for all timepoints	14 Days dosing period for Cohort 1, 28 Days dosing period for Cohort 3 and 14 Days follow-up period for all Cohorts